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IMPORTANCE The accumulation of aggregated β-amyloid and tau proteins into plaques and
tangles is a central feature of Alzheimer disease (AD). While plaque and tangle accumulation
likely contributes to neuron and synapse loss, disease-related changes to oligodendrocytes
andmyelin are also suspected of playing a role in development of AD dementia. Still, to our
knowledge, little is known about AD-relatedmyelin changes, and even when present, they
are often regarded as secondary to concomitant arteriosclerosis or related to aging.
OBJECTIVE To assess associations between hallmark AD pathology and novel quantitative
neuroimagingmarkers while being sensitive to white matter myelin content.
DESIGN, SETTING, AND PARTICIPANTS Magnetic resonance imagingwas performed at an
academic research neuroimaging center on a cohort of 71 cognitively asymptomatic adults
enriched for AD risk. Lumbar punctures were performed and assayed for cerebrospinal fluid
(CSF) biomarkers of AD pathology, including β-amyloid 42, total tau protein, phosphorylated
tau 181, and soluble amyloid precursor protein. Wemeasured whole-brain longitudinal and
transverse relaxation rates as well as themyelin water fraction from each of these individuals.
MAIN OUTCOMES ANDMEASURES Automated brainmapping algorithms and statistical models
were used to evaluate the relationships between age, CSF biomarkers of AD pathology, and
quantitative magnetic resonance imaging relaxometry measures, including the longitudinal
and transverse relaxation rates and themyelin water fraction.
RESULTS Themean (SD) age for the 19male participants and 52 female participants in the
study was 61.6 (6.4) years. Widespread age-related changes to myelin were observed across
the brain, particularly in late myelinating brain regions such as frontal white matter and the
genu of the corpus callosum. Quantitative relaxometry measures were negatively associated
with levels of CSF biomarkers across brain white matter and in areas preferentially affected in
AD. Furthermore, significant age-by-biomarker interactions were observed betweenmyelin
water fraction and phosphorylated tau 181/β-amyloid 42, suggesting that phosphorylated tau
181/β-amyloid 42 levels modulate age-related changes in myelin water fraction.
CONCLUSIONS AND RELEVANCE These findings suggest amyloid pathologies significantly
influence white matter and that these abnormalities may signify an early feature of the
disease process. We expect that clarifying the nature of myelin damage in preclinical ADmay
be informative on the disease’s course and lead to newmarkers of efficacy for prevention and
treatment trials.
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T heprogressionofAlzheimerdisease (AD)pathologyoc-curs several years before the development of demen-tia. According to the amyloid-cascade hypothesis, the
disruption of critical metabolic processes that lead to the ul-
timate neurodegeneration inAD is initiated by the accumula-
tion of aggregated β-amyloid 1-42 (Aβ1-42) and the assembly
of neurofibrillary tangles.1 Such processes are clearly detri-
mental to neuronal cell bodies, dendrites, and axonal pro-
cesses; however, myelin andmyelin-producing oligodendro-
cytes may be equally vulnerable to the impairments caused
by Aβ and tau protein hyperphosphorylation.2 White matter
hyperintensities (WMHs) play a role in symptom presenta-
tion but are not core features of AD pathology.3 Postmortem
and in vivo magnetic resonance imaging (MRI) studies have
substantiated recent hypotheses of white matter involve-
ment in AD, finding reducedwhitematter volume and altera-
tions of white matter microstructure.4-6 Still, little is known
about the relationship between Aβ pathology and myelin
alteration.
Recent advancements of cerebrospinal fluid (CSF) bio-
markers show promise for early detection of AD pathology.
Concentrations of specific proteins within CSF, such as
Aβ42, total tau protein (Ttau), and phosphorylated tau 181
(Ptau181), are related to the core pathology of AD7-9 and dif-
ferentiate patients with AD from healthy, age-matched
controls.10 Cerebrospinal fluid biomarkers have additionally
been linkedtomeasuresobtainedwithvolumetricMRIanddif-
fusion tensor imaging, suggesting that CSF biomarkers are
sensitive to structural brain changes during the preclinical
stages, onset, and progression of AD.4 Relationships be-
tween CSF biomarkers and brain structure are increasingly
important4,11; however, while MRI techniques provide de-
tailed anatomical andmicrostructural insight, they are influ-
encedbyabroad rangeofmicrostructural changes.12Thus, the
biological interpretation of such associations is challenging.
The breakdown of the myelin sheath may be an early
phenomenon in AD,5,13 but more clinical studies are needed,
especially in thepreclinical stage.RecentquantitativeMRImea-
sures, such as longitudinal and transverse relaxation rates (R1
andR2, respectively)andthemyelinwater fraction (MWF),may
provide increased sensitivity tomyelin content,14,15 and these
may offer new insights regarding the role of myelin vulner-
ability in thepathogenesis ofAD. Examining relationships be-
tween white matter measures and CSF biomarkers related to
ADpathology—such as Aβ42 (reflecting cortical amyloid dep-
osition), Ttau (as amarker for the intensity of neurodegenera-
tion),andPtau181 (correlatingwithtangleburden)16—couldpro-
vide an appreciation for the extent and timing of myelinated
white matter damage in AD. To our knowledge, no studies to
datehaveexploredsuch relationsat thepreclinical stageofAD.
However, evidence of such relationships may support and
transformthecurrentunderstandingof the involvementofmy-
elinated white matter and its alterations during the develop-
ment of AD.
We report results from 71 late-middle–aged asymptom-
atic adults who underwent CSF collection via lumbar
puncture17 and novel MRI using the Multicomponent
Driven Equilibrium Single Pulse Observation of T1 and T2
(mcDESPOT) technique. These data were acquired to exam-
ineADpathology as indexedbyCSFbiomarkers and theMWF,
a surrogate measure of myelin content.15,18 Guided by prior
models and observations,4 we hypothesized that the deposi-
tion of Aβ42 and the hyperphosphorylation of tau protein
would affect oligodendrocytes and altermyelin sheath integ-
rity. Hence, we predicted decreased Aβ42 and elevated Ttau
and Ptau181 levels would be associated with decreased MWF.
Weadditionallyhypothesized thatproteins that precedeAβ42
formation, including elevated cleavageof the amyloidprecur-
sor protein by β-secretase that results in higher soluble amy-
loid precursor protein (sAPPβ), may stimulate processes of
white matter alteration and be associated with myelin con-
tent alterations in the preclinical phase.
Methods
A total of 147 participants were enrolled in the study, from
which 71 asymptomatic participants (19 males) between
the ages of 48 and 72 years (mean [SD] age = 61.6 [6.4] years)
were included based on the availability of assayed CSF and
mcDESPOT imaging.Healthy community volunteerswere re-
cruited from theWisconsin Alzheimer Disease Research Cen-
ter and the Wisconsin Registry for Alzheimer’s Prevention
study.17Participantsunderwentassessments that includedneu-
ropsychological testing, apolipoprotein E (APOE) genotyp-
ing, laboratory tests, clinicalmeasurements, and comprehen-
sive health history characterization.17 Twenty-eight
participants (39%)were carriers of at least 1APOE ε4allele and
54 participants (76%) had a parental history of AD. Inclusion
criteria consistedof the following: apriorvisit for lumbarpunc-
ture, no contraindications for MRI, and a subsequent normal
MRI scan finding. Cardiovascular health was assessed using
the Framingham cardiovascular risk score and further inclu-
sion was limited to participants who scored 27 or greater on
the Mini-Mental State Examination.19 Written informed con-
sent was obtained from all study participants and the study
procedureswereperformedunder guidelines approvedby the
University of Wisconsin Health Sciences institutional review
board. Additional participant information is available in the
eMethods in the Supplement while demographic informa-
tion is provided in the Table.
Key Points
Question What are the underlying relationships between white
matter microstructure and, more specifically, myelin content and
cerebrospinal fluid biomarkers of Alzheimer disease?
Findings In this cohort study of asymptomatic individuals with
genetic risk factors for Alzheimer disease, significant associations
were observed between quantitative neuroimagingmeasures,
including themyelin water fraction and cerebrospinal fluid
biomarkers of Alzheimer pathology.
Meaning Mechanisms of amyloid pathology influence and alter
the white matter microstructure, whichmay indicate an early
feature of Alzheimer disease.
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CSF Collection
Cerebrospinal fluid was collected via lumbar puncture using
a Sprotte 25- or 24-gauge spinal needle at the L3/4 or L4/5
level of the spinal column the morning after a 12-hour over-
night fast. Lumbar punctures were performed an average of
5.86 days prior to brain imaging. Approximately 22 mL of
CSF were extracted, mixed, and centrifuged at 2000g for 10
minutes. Supernatants were frozen in polypropylene tubes
in 0.5-mL aliquots and stored at -80°C. Samples were ali-
quoted in sterile polypropylene collection tubes and stored
in a 280uC freezer. The samples were subsequently sent in a
single batch to the Sahlgrenska University Hospital at the
University of Gothenburg in Sweden, where CSF was
assayed for Aβ42, Ttau, and Ptau181 using commercially
available enzyme-linked immunosorbent assay methods
(INNOTEST assays; Fujiurebio).20 Cerebrospinal fluid
sAPP-β was measured using the Meso Scale Discovery Multi-
plex Soluble APP assay according to the manufacturer’s
instructions. Board-certified laboratory technicians, blinded
to clinical information, analyzed all samples according
to protocols approved by the Swedish Board of Accredita-
tion and Conformity Assessment. One batch of reagents
was used yielding intra-assay coefficients of less than 10%
variation.
MRI Data Acquisition and Processing
Participantswere imagedona3TGeneral ElectricMR750Dis-
covery scanner (General Electric Healthcare) with an 8-chan-
nel receive-onlyheadcoil (NovaMedical).ThemcDESPOTpro-
tocol includedboth spoiledgradient-recalledecho images and
balanced steady-state free precession images acquired over
multiple flip angles (eFigure 1 in the Supplement).15 All im-
ages were acquired sagittally and shared a common field of
view of 25.6 cmby 25.6 cmby 16.8 cmwith an isotropic voxel
resolution of 2mm3.Acquisition time for themcDESPOTpro-
tocol was approximately 8 minutes per participant. Addi-
tional sequence-specific parameters are provided in the
eMethods in the Supplement.
R1, R2, andMWFmapswere calculated and aligned to the
Montreal Neurological Institute template space, as described
in eMethods in the Supplement. TotalWMHvolumewas also
measured using high-resolution T1-weighted and T2-
weighted images and the Lesion Segmentation Toolbox ver-
sion 1.2.2 in Statistical Parametric Mapping 8 (http://www.fil
.ion.ucl.ac.uk/spm/), normalized by the total intracranial
volume and log-transformed for the inclusion of statistical
analyses.
Statistical Analysis
Relationships of Age, CSF Biomarkers, and ImagingMeasures
The single greatest risk factor for AD is age,21 and thus our
initial analyses examined the relationship between age and
the CSF biomarkers as well as age and the imaging measures
(MWF, R1, and R2). To examine the relationships between
age and CSF biomarkers, Pearson correlations were calcu-
lated in R (version 3.2.1).22 Significant correlations were
defined as P < .05, Bonferroni-corrected for 28 independent
comparisons.
Age-related changes in R1, R2, and MWF were examined
by fitting linear models at each brain voxel contained within
awhitemattermask (eFigure2 in theSupplement).Eachmodel
examinedR1, R2 andMWFas a functionof age,while account-
ing for sex, APOE carrier status, log-transformed normalized
WMH volume, and the Framingham cardiovascular risk
score due to known effects on brain microstructure.23 We
examined education level and family history as additional
nuisance variables; however, no significant relationships
were observed by including these variables. Statistical maps
were thresholded at a level of P < .05, corrected for multiple
comparisons using the false discovery rate (FDR)24 at the
voxel level.
Relationships Between CSF Biomarkers andMWF
Voxelwise linear regressions were fit to examine relation-
shipsbetweenR1,R2, andMWFandconcentration levelsofCSF
biomarkers. Individual CSF biomarkers, as well as biomarker
ratioswith Aβ42,were used as predictor variables, while age,
sex,APOE status, Framingham cardiovascular risk score, and
log-transformed normalized WMH volume were covariates.
Analyses were constrained to white matter and the FDR cor-
rected for multiple comparisons.
After establishing significant findingsbetweenageand re-
laxometry measures as well as between R1, R2, andMWF and
CSF biomarkers, we used additional models to examine
whether concentrations of CSFbiomarkersmoderated the ef-
fect of age on the brain’s MWF, R1, and R2. Predictors in these
voxelwise models included age, CSF biomarker concentra-
tion, and the interactionsofCSFbiomarker concentrationwith
age,aswell as thecovariatesof sex,APOE, log-transformednor-
malized WMH volume, and Framingham cardiovascular risk
score.
Table. Demographic Characteristics of Participants
Characteristic Mean (No. of Days)
No. of participants 71
Age, mean (SD), y 61.6 (6.4)
Sex
Male 19
Female 52
APOE4 carriers (e4e4/e4e3)/noncarriers 28 (2/26)/43
AD parental history
Positive 54
Negative 17
Education, y 16.96 (2.57)
MMSE score 29.36 (1.00)
RAVLT score
Trial 1 6.74 (1.90)
Trials 2-5 45.96 (6.36)
Delay 10.97 (2.88)
TMT Part B, s 60.07 (22.49)
No. of days between MRI and lumbar puncture,
mean (range), d
37.22 (0-205)
Abbreviations: AD, Alzheimer disease; APOE4, apolipoprotein E4 allele; MMSE,
Mini-Mental State Examination; MRI, magnetic resonance imaging; RAVLT, Rey
Auditory Verbal Learning Test; TMT, Trail-Making Test.
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Results
Changes in CSF Biomarkers and ImagingMeasuresWith Age
Age at time of lumbar puncture was not significantly associ-
ated with CSF biomarkers (Pearson correlations shown in
eTable 1 in the Supplement).
Widespread age-related changes (P < .05, FDR corrected)
were observed, particularly in late myelinating brain regions
such as frontal whitematter and the genu of the corpus callo-
sum (Figure 1). Myelin water fraction was negatively related
to age, suggesting an overall decrease inmyelin content with
aging. R1 decreased in similar brain regions, including frontal
white matter and the genu of the corpus, while R2 decreased
with age across most white matter. Summary information is
provided in eTable 2 in the Supplement. These findings sug-
gest alterations to microstructural white matter and perhaps
specifically inmyelin content; however, such changesmaybe
a result of increases of bulk water content or other biologi-
cally based changes.25 Such findings are consistent with
reported literature of age-related declines of white matter
during typical and atypical aging.26
Relationships Between CSF Biomarkers
and ImagingMeasures
Voxelwise regressions between CSF biomarkers and imaging
measures revealed widespread and robust main effect asso-
ciations. LowerAβ42was associatedwithdecreasedMWF,R1,
Figure 1. Associations Between Age andQuantitative RelaxometryMeasures
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A, Significant (P < .05, false discovery rate [FDR] corrected) age-related
relationships with myelin water fraction (MWF) (top row), R1 (middle row), and
R2 (bottom row) overlaid on the groupmeanMWFmap. Negative relationships
were observed across widespread white matter, with late myelinating areas,
including frontal and temporal white matter, having the strongest age-related
declines. B, representative scatterplot depicts themeanMWF, R1, and R2
calculated from areas of significant age decline plotted against the age of each
participant. Scatter points represent individual mean parameter (MWF, R1, and
R2) values and the solid trend line represents the line of best fit with age.
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and R2. R2 displayed the most extensive relationships, fol-
lowed by MWF and R1 (eTables 3-5 in the Supplement). Rela-
tionships were primarily located within the left hemispheric
angular gyrus white matter for MWF and R1, while associa-
tions with R2 were found across the left hemispheric tempo-
ral andparietalwhitematter and inferior longitudinal fascicu-
lus.Other less localizedwhitematter regionswereadditionally
implicated (eFigure 3 in the Supplement).
Weobservedsignificantnegative relationships (P<.05,FDR
corrected)betweenMWF,R1,andR2andCSFbiomarkersofTtau,
Ttau/Aβ42,Ptau181,Ptau181/Aβ42,sAPPβ,andsAPPβ/Aβ42.Rep-
resentative findingsbetweenMWFandsAPPβ/Aβ42are shown
in Figure 2while relationships between MWF, R1, and R2 and
otherCSFbiomarkers are shown ineFigures4-6 in theSupple-
ment.Wehighlight thenegativeassociationbetweenMWFand
sAPPβ/Aβ42 in representative scatterplots in Figure 3. Rela-
tionships with MWF were extensive across white matter and
discovered in the frontal, temporal, parietal, and cerebellar
white matter. Soluble amyloid precursor protein/Aβ42
showed the strongest effect with regions known to be
preferentially affected by AD, including temporal and frontal
white matter, the body of the corpus callosum, and the
cingulum.27 We found negative relationships between CSF
biomarkers and R1 in the cingulum, inferior fronto-occipital
fasciculus, and the superior longitudinal fasciculus, with
extensive relationships occurring with sAPPβ/Aβ42. We also
observed negative associations with R2, with relations
between R2 and Ptau181/Aβ42 having the largest impact.
CSF BiomarkersModerateMyelin Content Age Relationships
We observed significant (P < .05, FDR corrected) age-
by-biomarker interactions. In particular, we found relation-
ships betweenMWFandPtau181/Aβ42 in left hemispheric su-
perior frontal gyral white matter and portions of the left
superior longitudinal fasciulus in which higher levels of
Ptau181/Aβ42 resulted in an increasedMWF decline with age
(Figure 4). We provide a summary and depiction of the inter-
action results in eTable 6 and eFigure 7 in the Supplement.
Discussion
Alzheimer disease disrupts critical metabolic processes that
ultimately lead to neurodegeneration; however, the effect of
AD pathology on white matter—especially myelin—is still
incompletely characterized. Using CSF biomarkers of AD to-
gether with quantitative relaxometry measures in cogni-
tively asymptomaticmiddle-aged adults enriched forAD risk,
we have demonstrated significant associations between AD
pathologyandmeasuresofmyelinhealth invivo.Elevatedcon-
centrations of Ttau, Ptau181, and sAPPβ—alongwith elevated
ratios of Ttau/Aβ42, Ptau181/Aβ42, and sAPPβ/Aβ42—were ro-
bustly associatedwithdecreasedMWF,R1, andR2acrosswide-
spreadbrain regions.Theeffectofageonthe trajectoryofMWF
wasmoderatedby ratios of Ptau181/Aβ42andTtau/Aβ42,with
elevated ratios leading to acceleratedMWFdecline. This is the
first study, to our knowledge, to demonstrate relationships
between AD pathology and relaxometry measures and
further reinforce recent findings that AD pathology has an
important impact on white matter microstructure.4
Our findings provide evidence that risk factors for devel-
oping AD are related to alterations ofmyelin content. Specifi-
cally, we find that age highly associates withMWF, R1, and R2
decreases. These findings agree with studies showing white
matter volume andmicrostructure to follow anegative gradi-
ent throughout later stages of life.13,28 Our results agree with
hypothesesof latemyelinatingbrain regions29,30being the first
todegeneratewithage26 and implicated inAD.31 Together, this
suggests that white matter alterations may be centrally in-
volved in AD pathogenesis. Analyses of MWF and age were
performed using linear regressions as the age range of par-
ticipants did not appear to capture the nonlinearity of the
MWF trajectory. However, the brain follows a nonlinear
trajectory,26,32 andthus futurestudiesusing larger samplesand
wider age ranges should examinewhetherMWF follows such
a nonlinear trajectory. Such information would improve un-
derstanding about the timing of AD pathology, including the
initial periods of myelin decline.
WeadditionallyshowrobustassociationsbetweenCSFbio-
markers andmyelin content asmeasured byMWF,R1, andR2.
Amyloid pathology has classically been linked with pro-
cesses underlying neuronal degeneration; however, studies
have revealed myelin and oligodendrocytes to be especially
vulnerable to impairments ofAβpathology.5Myelinbasic pro-
tein, a canonical protein component of myelin, has recently
been shown to bind Aβ and inhibit Aβ fibril formation, possi-
bly playing a role in regulating the deposition of Aβ42 and the
Figure 2. RegionalWhiteMatterMyelin Content, asMeasured byMyelin
Water Fraction (MWF), AssociatedWith Soluble Amyloid Precursor
Protein/β-Amyloid 42 (sAPPβ/Aβ42)
.05 <.0001P value (FDR corrected)
L
Representative axial slices depicting areas of significant relationship between
MWF and sAPPβ/Aβ42 overlaid on the groupmeanMWFmap. Widespread
white matter was observed to be negatively related to levels of sAPPβ/Aβ42.
Results are false discovery rate (FDR) corrected for multiple comparisons
(P < .05).
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formation of amyloid plaques in parenchyma.33,34 Therefore,
the loss of myelin and decreases in concentrations of myelin
basic proteinmay promote acceleratedAβ42 depositions and
result in increasedamyloidplaque formation. Studieshavead-
ditionallydemonstrated thatmyelin abnormalities occurprior
to axondefects from tau proteins inhibiting axon transport,35
meaning thatmyelination defects precede overt amyloid and
tau pathologies.36
Interestingly, we observed strong associations of de-
creased myelin content with increased ratios of sAPPβ and
sAPPβ/Aβ42, with sAPPβ/Aβ42 having the greatest sensitiv-
ity. β-Amyloid is aproduct of amyloidprecursor protein cleav-
age byβ-secretase,whichultimately leads to the formationof
amyloid plaques.5 Animal studies using immunohistochem-
istry and electron microscopy on the triple-transgenic AD
mouse, which harbors the amyloid precursor protein trans-
gene, have found localized alterations inmyelination andoli-
godendrocytemarker expressionprior to themanifestationof
amyloid and tau pathologies.36 Findings from these previous
studies in thecontextof thecurrent studyraisequestionsabout
the role of sAPPβ in myelin alterations of AD pathology. The
remaining challengeof deciphering the causalmechanismsof
these changes is determining if aberrant proteolytic process-
ing of the amyloid precursor protein causes subsequent my-
elindamageor if degradationofmyelin results in altered amy-
loidprecursorproteinprocessing.Weneed further animal and
human studies to elucidate this causal pathway.
Our findings also indicate that the strengthof the relation-
ship betweenMWFand age is altered by the ratios of Ptau181/
Aβ42 and Ttau/Aβ42. While tau pathology may follow amy-
loidpathology,hyperphosphorylationof tauproteinalsooccurs
during the repair of the myelin sheath.5 Increased concen-
trations of Ttau and Ptau181 may reflect initial benefits to
remyelination5,13 and the effects of moderate myelin break-
down with aging. One hypothesis is that extensive time-
limited repair and/or unsuccessful repair could lead to pro-
tein aggregation and deposition as neurofibrillary tangles.5
Limitations
This study has several limitations. First, while the sample
provides a powerful cohort for investigating relationships of
CSFbiomarkers andbrainmicrostructure, theenriched risk for
AD (largepercentage of family historypositive– andAPOE ε4–
positive individuals), as well as the low percentage of males
Figure 3. Associations Between Soluble Amyloid Precursor Protein (sAPPβ)/β-Amyloid 42 (Aβ42) andMyelinWater Fraction (MWF)
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(19%),could limit thegeneralizabilityofourfindings.Familyhis-
tory was found to have a nonsignificant effect on the findings
of the current study. APOE status was included as a nuisance
variable;however, it ispossible thatAPOEallele statusmay im-
pactbrainaging26,28 and that future studiesexaminingsuch re-
lationships could be informative. Second, while qualitative
agreement has been observed between mcDESPOTMWF and
histology,37 and strong evidence has beenprovided to support
theapplicationofmcDESPOTMWF,29,30,38-40 future studies in-
vestigating the specificity and sensitivity of mcDESPOT-
derivedMWFmeasurementscomparedwithadditional factors—
such as changes to brain volume, water content, iron load, or
microstructural lipidsandproteins—arenecessary.While there
was an overlap in findings with MWF, R1, and R2, associations
indifferentbrain structuresbetweenbrainmeasureswerealso
observed, suggesting that these measures are complimentary
butmayelucidatedifferentialmicrostructuralprocesses.29Last,
cross-sectional analyses have permitted us to examine the as-
sociations between CSF biomarkers and neuroimaging mea-
sures. However, these findings should be explored in larger
samples and extended in longitudinal samples to evaluate the
time course of these relationships.
Conclusions
Myelinalterations inADare suspectedbutunderstudied inhu-
man populations. Using a quantitative MRI technique sensi-
tive to myelination, we measured CSF biomarkers and my-
elin content to examine the relationships between AD
pathology. Our findings show, for the first time to our knowl-
edge, that decreased concentrations of Aβ42 and elevated
Figure 4. Levels of Phosphorylated Tau (Ptau181)/β-Amyloid 42 (Aβ42)Moderate Age-Related Changes ofMyelinWater Fraction (MWF)
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A, Representative illustration of significant interactions of age and Ptau181/Aβ42 with MWF. Myelin water fraction from the peak voxel (as indicated by the
cross-hair) was extracted and participants were subsequently split into 2 groups by the Ptau181/Aβ42 ratio median. B, Myelin water fraction was plotted and fit
against participant age for each group. These plots demonstrate the changing age relationship with dissimilar Ptau181/Aβ42 ratio.
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concentrations of Ttau, Ptau181, sAPPβ, and their ratios with
Aβ42 are closely associated with brain myelin content. Fur-
thermore, we show that the age-related decline in myelin
content is influenced by the levels of CSF biomarkers. These
findings provide further evidence of white matter involve-
ment, andparticularlymyelin content, in the pathogenesis of
AD and suggest that such alterations may be one of the earli-
est characteristics of the disease process.
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